Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular diseases in patients with CKD are unique and grouped as uremic vascular ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

Downstream in the immune cascade, TYK2 inhibitors of the IL-12 and IL-23 pathway involved in psoriasis and Crohn’s disease are gaining momentum, as they avoid impact on haematopoiesis compared ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

智通财经APP讯，康方生物(09926)发布公告，中国国家药品监督管理局(NMPA)已于近日批准爱达罗®(依若奇单抗，IL-12/IL-23)的新药 ...